These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2064384)

  • 1. Biologically based pharmacodynamic models: tools for toxicological research and risk assessment.
    Conolly RB; Andersen ME
    Annu Rev Pharmacol Toxicol; 1991; 31():503-23. PubMed ID: 2064384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologically based modeling in toxicology research.
    Andersen ME; Krishnan K; Conolly RB; McClellan RO
    Arch Toxicol Suppl; 1992; 15():217-27. PubMed ID: 1510591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.
    Kenyon EM; Klimecki WT; El-Masri H; Conolly RB; Clewell HJ; Beck BD
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):359-68. PubMed ID: 18687352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating additional biological phenomena into two-stage cancer models.
    Sielken RL; Bretzlaff RS; Stevenson DE
    Prog Clin Biol Res; 1994; 387():237-60. PubMed ID: 7972250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-incidence modeling: consequences of linking quantal measures of response to depletion of critical tissue targets.
    Andersen ME; Lutz RW; Liao KH; Lutz WK
    Toxicol Sci; 2006 Jan; 89(1):331-7. PubMed ID: 16237194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.
    Dahl SG; Aarons L; Gundert-Remy U; Karlsson MO; Schneider YJ; Steimer JL; Trocóniz IF
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):2-12. PubMed ID: 19686541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormesis is central to toxicology, pharmacology and risk assessment.
    Calabrese EJ
    Hum Exp Toxicol; 2010 Apr; 29(4):249-61. PubMed ID: 20332169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of industrial toxicology toward vanishing doses and the human genome].
    Colombi A; Buratti M; Rubino FM; Giampiccolo R; Pulvirenti S; Brambilla G
    Med Lav; 2003; 94(1):69-82. PubMed ID: 12768958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
    Kitchin KT; Conolly R
    Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Nov; (531):1-218. PubMed ID: 17342196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically based dose-response modeling in developmental toxicology: biochemical and cellular sequelae of 5-fluorouracil exposure in the developing rat.
    Shuey DL; Lau C; Logsdon TR; Zucker RM; Elstein KH; Narotsky MG; Setzer RW; Kavlock RJ; Rogers JM
    Toxicol Appl Pharmacol; 1994 May; 126(1):129-44. PubMed ID: 8184423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.